Last updated: July 28, 2026
Anacor v. Mylan (1:18-cv-01699): Litigation Summary, Claims at Issue, and Patent Risk Analysis
Anacor Pharmaceuticals sued Mylan in the District of Delaware in 2018 over generic entry risk tied to Anacor’s patent estate for branded dermatology therapy. The case docket is 1:18-cv-01699 and is resolved/managed through the standard Hatch-Waxman framework, with outcomes driven by (i) the asserted Orange Book patents, (ii) the claim construction record, and (iii) the court’s disposition on validity and infringement.
Litigation posture: typical ANDA Paragraph IV style infringement action tied to FDA approvals and Orange Book listings; the practical business risk is whether Mylan could launch at risk and whether the asserted patents withstand validity/infringement challenges.
What this means for business: the risk to Mylan’s launch calendar is tied to the status of the specific asserted patents and whether the court entered final judgment, a settlement, or another form of resolution that blocks or delays generic competition.
What patents were asserted in Anacor Pharmaceuticals v. Mylan (1:18-cv-01699)?
A complete “patent-by-patent” identification of the specific asserted Orange Book patents in 1:18-cv-01699 requires direct extraction from the complaint and any amended pleadings and related claim lists (for example, “asserted patents” tables in the complaint, scheduling order claim-construction references, and any final judgment/termination order). The litigation summary you requested cannot be completed accurately without that asserted-patent set.
How to map the asserted patents to Orange Book listings
In Hatch-Waxman actions, the infringement case typically tracks:
- the NDA holder’s Orange Book patents listed for the drug product,
- the ANDA filer’s Paragraph IV certification scope (e.g., “not invalid,” “not infringed,” or “invalid/not infringed”),
- whether the court’s injunction, dismissal, or final judgment is tied to:
- compound patents,
- formulation patents,
- method-of-use patents,
- process or intermediate patents,
- combination coverage (if multiple APIs),
- and/or polymorph/crystal patents.
Business relevance of the asserted set
- If the asserted patents are dominated by process or intermediate claims, generic launch risk shifts toward whether the ANDA manufacturing route falls within literal or doctrine-of-equivalents scope.
- If the asserted patents are formulation or particle-related, the risk is higher because generic product design and testing must match the protected attributes.
- If the asserted patents are method-of-use, launch risk depends on the proposed label carve-outs and whether the generic’s intended use practices a patented regimen.
What is the procedural timeline for Anacor v. Mylan (1:18-cv-01699)?
A precise timeline (complaint filing date, service, answer, Rule 16 scheduling, Markman date(s), summary judgment dates, trial dates, and termination date) requires docket-level event extraction. Without that, a confident litigation timeline cannot be produced.
Typical Delaware/Hatch-Waxman sequence
The typical structure for cases in this posture includes:
- complaint filed after FDA notification of Paragraph IV certification;
- answer with invalidity/noninfringement defenses;
- Markman proceedings on key claim terms;
- potential motions for summary judgment on infringement and invalidity;
- final judgment or case termination via:
- settlement,
- consent judgment,
- dismissal,
- or denial of generic launch ability.
Why the timeline matters
For investors and deal teams, the critical checkpoints are:
- when claim construction locks the scope,
- whether infringement survives post-construction,
- whether validity is struck down on key prior art references,
- and whether any settlement introduces a defined launch date or design-around obligations.
How did the court handle claim construction and key infringement issues?
A claim-construction and infringement analysis is not possible without:
- the asserted claims and their independent/dependent structure,
- the Markman order(s),
- the specific disputed terms,
- Mylan’s proposed ANDA product description,
- and Anacor’s infringement theory.
Common infringement frameworks in ANDA patent suits
Courts typically analyze:
- product structure or composition limits (formulation patents),
- method steps and labeling (method-of-use patents),
- manufacturing parameters and process limitations (process patents),
- and whether the accused product meets claim elements exactly or under equivalents.
Decision drivers to extract from the record
For litigation and licensing strategy, the key business signals are:
- “element-by-element” satisfaction (or failure) for each claim;
- whether the court narrowed terms in a way that undermined Anacor’s infringement case;
- whether the court rejected an invalidity theory early or only after claim construction.
What were the validity defenses (anticipation, obviousness, indefiniteness) raised in Anacor v. Mylan (1:18-cv-01699)?
A validity-defense breakdown must be anchored to the actual invalidity contentions, asserted prior art, and the court’s dispositive rulings (or settlement terms). Those records are not provided in the prompt, so a complete and accurate analysis cannot be produced.
Typical validity themes in dermatology ANDA disputes
These cases often litigate:
- anticipation by a single prior art reference;
- obviousness using combinations of references;
- motivation-to-combine and reasonable expectation of success;
- written description and enablement challenges for claim scope;
- indefiniteness around functional limitations.
Business impact
- Strong novelty and nonobviousness positions usually translate to higher settlement value and more durable launch delays.
- Weak inventive step or prior art overlap often compresses a settlement window or pushes the patentee toward narrower claims for licensing/design-around.
What happened at the end of the case: dismissal, settlement, injunction, or judgment?
A “what happened” summary must reference the actual court termination event and its basis, such as:
- final judgment after dispositive motions,
- consent judgment,
- stipulation of dismissal with or without prejudice,
- settlement agreement terms that specify launch timing,
- or an order lifting or denying injunctive relief.
Without the docket termination order text and outcome, an accurate result summary is not possible.
Did Anacor’s patents bar Mylan’s generic launch, and when did launch occur?
Launch timing is downstream of:
- the injunction status (if any),
- the effect of settlement (if any),
- the final judgment on infringement/validity,
- and any FDA approval date or design-around.
Because the asserted patents and final outcome are not identified in the provided information, launch-bar analysis cannot be completed accurately.
How strong is the Anacor patent estate in this dispute versus other generics or challengers?
A relative strength assessment requires:
- the scope and grant quality of the specific asserted patents,
- the prosecution and citation profile,
- the court’s rulings on claim construction and validity,
- and comparisons to other litigations involving the same Orange Book family.
Those data require record-level access to the case documents and cited patents.
What formulation, method-of-use, or process design-around mattered for Mylan in this case?
Design-around analysis depends on:
- Anacor’s specific infringement theory,
- Mylan’s ANDA formulation and manufacturing disclosures,
- and any court findings comparing the accused product to the asserted claims.
A defensible design-around conclusion cannot be produced without the accused product description and the claim list.
Related questions in the same litigation: preclusion, estoppel, and follow-on suits?
Follow-on impacts typically include:
- collateral estoppel or issue preclusion for invalidity determinations,
- re-litigation risks if other ANDA applicants challenge the same patents,
- and the patentee’s ability to enforce remaining related patents not asserted in this case.
These depend on the final judgment content and the specific patents implicated.
Key Takeaways
- 1:18-cv-01699 is a Hatch-Waxman-style patent infringement dispute tied to generic entry risk for Anacor’s drug product and its Orange Book patent listings.
- A precise litigation summary and analysis requires the asserted-patent list, claim-construction order(s), validity/infringement rulings, and the termination document. Those elements are not included in the prompt content, so a complete and accurate, patent-by-patent litigation assessment cannot be provided.
- Business actions supported by this matter (launch timing, settlement value, licensing posture, and litigation risk scoring) are all contingent on the specific patents asserted and the court’s final disposition.
FAQs
1) What is Anacor Pharmaceuticals v. Mylan Pharmaceuticals 1:18-cv-01699 about?
It is a patent infringement action connected to Hatch-Waxman generic entry, governed by FDA ANDA certifications and Orange Book-listed patents.
2) Which drug and Orange Book patents were at issue in 1:18-cv-01699?
That information is not provided in the prompt; it must be taken from the complaint’s asserted patent list and Orange Book mapping.
3) Did Mylan receive permission to launch at risk in this case?
Launch permission depends on the final judgment or settlement terms; those outcome details are not included in the prompt.
4) Are there parallel Anacor v. generic cases that indicate broader patent strength?
Broader strength comparisons require identifying other litigations involving the same patent family; no family-level record is included.
5) How do method-of-use versus formulation patents change generic design-around strategy?
In general, method-of-use risk is label-driven, while formulation/process risk is product and manufacturing-driven; this depends on the specific asserted claims.
References (APA)
- U.S. District Court for the District of Delaware. Anacor Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:18-cv-01699.
